PTC Therapeutics has launched a Phase 3 clinical trial to evaluate its investigational oral therapy vatiquinone ( PTC743 ) in children and young adults with Frederich’s ataxia (FA). The international trial had experienced earlier delays due to the COVID-19 pandemic . Called MOVE-FA ( NCT04577352 ), it is meant […]
Click here to view original web page at friedreichsataxianews.com